Kwality Pharma’s Leuprorelin Acetate Entry Boosts EU Market Presence

Kwality Pharmaceuticals Limited (KPL) has approved its Leuprorelin Acetate 11.25 mg vial powder with a solvent for injectable suspension in Greece as the company's site variant in Europe. The three validation batches will arrive in December, after which regular shipments will be made in January 2025 after proper Quality Control Analysis.

This strategic CDMO partnership is expected to bring in around USD 3 million of annual revenue; it is scheduled to start sales in the 4th quarter of this fiscal year. The company also aims to add more strengths of the same product along with the same customer. This shall represent an essential milestone in Kwality Pharma's journey of expansion into this highly regulated market.